论文部分内容阅读
目的探讨重组人促红细胞生成素治疗心力衰竭合并肾功能不全患者的临床疗效。方法选取84例心力衰竭合并肾功能不全患者,采用随机数字表法将其分为治疗组(42例)与对照组(42例),两组均给予常规治疗,治疗组在此基础上加用重组人促红细胞生成素,治疗12周后,比较两组患者的心脏超声及肾功能。结果治疗组患者心脏超声及肾功能各项指标均较对照组为高,差异有统计学意义(P<0.05)。结论重组人促红细胞生成素可明显改善心力衰竭合并肾功能不全患者的心室重塑及肾功能。
Objective To investigate the clinical efficacy of recombinant human erythropoietin in the treatment of patients with heart failure and renal insufficiency. Methods Eighty-four patients with heart failure and renal dysfunction were selected and divided into treatment group (n = 42) and control group (n = 42) by random number table. Both groups were given routine treatment. The treatment group was added on the basis of this Recombinant human erythropoietin, after 12 weeks of treatment, compared the two groups of patients with cardiac ultrasound and renal function. Results The indexes of cardiac ultrasound and renal function in the treatment group were higher than those in the control group (P <0.05). Conclusion Recombinant human erythropoietin can significantly improve ventricular remodeling and renal function in patients with heart failure and renal insufficiency.